B. Lanier, H. Neuman
Isosceles Pharmaceuticals, North Carolina, United States
Keywords: Traumatic Brain Injury (TBI), Neuroprotection, Warfighter Readiness, Blood-Brain Barrier (BBB), Point-of-Injury Care
Traumatic brain injury (TBI) is a major cause of combat-related morbidity, with few effective therapies available at the point of injury. Secondary injury processes including neuroinflammation, oxidative stress, blood-brain barrier (BBB) disruption, and impaired cerebral perfusion begin within minutes and drive ongoing neurological damage. IPI201 is being developed as a rapid, field-deployable neuroprotective therapy designed for use in austere environments. It delivers multimodal effects by reducing inflammatory signaling, preserving BBB integrity, decreasing oxidative stress, and supporting cerebral perfusion. Additionally, IPI201 attenuates inflammatory and neuropathic pain without causing sedation, helping maintain cognitive function in conscious casualties. IPI201 is formulated as a sterile, ready-to-use intravenous therapy suitable for Role 1 administration with minimal logistical burden. In rodent TBI models, doses of 5–20 mg/kg IV were administered within 1–4 hours post-injury. Evaluated endpoints included lesion volume, BBB permeability, inflammatory cytokines, oxidative stress markers, and neurobehavioral outcomes. Across studies, IPI201 demonstrated significant reductions in lesion volume, BBB disruption, inflammatory cytokines, and oxidative stress, along with improved neurobehavioral recovery. In separate studies, the active molecule also reduced both local and systemic inflammation more effectively than NSAID Meloxicam over 24 hours. Phase I human study will be completed in August 2026.